Novo Nordisk's CEO, Lars Fruergaard Jørgensen, appeared before the US Senate on Tuesday, facing intense scrutiny over the high prices of the company's popular weight-loss and diabetes drugs, Wegovy and Ozempic. These medications have become essential treatments for millions of Americans, but their elevated price tags have sparked widespread criticism from both lawmakers and patients.
During the hearing, led by Senator Bernie Sanders, the Senate Health, Education, Labor, and Pensions Committee pressed Novo Nordisk to reduce the costs of these life-changing drugs. In particular, the committee pointed out the stark price discrepancies between the US and other countries. For example, while Americans pay approximately $969 per month for Ozempic, patients in Germany pay only $59.
Novo Nordisk’s Justification: Structural Issues in the US Healthcare System
Jørgensen defended the company's pricing strategy, attributing the high costs to "structural issues" in the US healthcare system. He emphasized that middlemen, such as Pharmacy Benefit Managers (PBMs) and insurers, play a significant role in determining the final price of medications. These intermediaries, who negotiate drug prices and coverage, are crucial in whether or not patients can access the drugs through insurance.
Jørgensen also expressed willingness to negotiate lower prices with US lawmakers but insisted that any price reductions must be accompanied by assurances that the drugs will remain covered by insurance plans. Citing a previous instance when Novo Nordisk lowered the price of its insulin product Levemir, Jørgensen noted that insurers subsequently dropped the drug from coverage, dramatically reducing patient access.
The Role of PBMs in Drug Pricing
Pharmacy Benefit Managers (PBMs) have been a focal point in the discussion surrounding drug prices. These third-party administrators manage prescription drug benefits on behalf of insurers and negotiate directly with pharmaceutical companies. Senator Sanders has secured written commitments from major PBMs, including Optum and CVS Health's Caremark, to expand coverage for Wegovy and Ozempic if their prices are reduced.
By collaborating with PBMs and lawmakers, Novo Nordisk aims to strike a balance between profitability and accessibility. However, many US politicians argue that the burden of high prices disproportionately falls on patients.
Novo Nordisk's Market Dominance and Future Plans
The US remains Novo Nordisk's most lucrative market, with the company reporting a 41% increase in US sales in the second quarter of 2024. This growth has been driven largely by the demand for obesity and diabetes care products like Wegovy and Ozempic. However, supply shortages have been a persistent issue, leading the company to expand production capacity and even acquire US-based drug maker Catalent to maintain market share.
Analysts predict that price negotiations for these drugs may not occur until 2027, following the next round of price-setting discussions in February 2025. Until then, Novo Nordisk is expected to continue its dominance in the diabetes and obesity drug market, while facing ongoing scrutiny from US lawmakers and patients alike.
Novo Nordisk's high drug prices have become a central issue in the US healthcare debate. While the company’s CEO, Lars Fruergaard Jørgensen, remains open to negotiations, the involvement of PBMs, insurers, and systemic issues complicates the path to affordable access for American patients. The future of Wegovy and Ozempic pricing will depend on both political actions and the ability of the healthcare system to accommodate lower costs while maintaining coverage.
Source: Euronews
Comments